CD82 attenuates TGF-β1-mediated epithelial-mesenchymal transition by blocking smad-dependent signaling in ARPE-19 cells

Hyesook Lee1†, Jung-Hwa Han1,2†, Yun Jeong Kang1, Hyun Hwangbo3, Aeseon Yoon1, Hyung-Sik Kim4, Dongjun Lee1, Soo Yong Lee5, Byung Hyun Choi6, Jae-Joon Kim7, Seo Rin Kim8, Yung Hyun Choi3,9* and Jin Hur1,2*

1Department of Convergence Medicine, Pusan National University School of Medicine, Yangsan, South Korea, 2PNU GRAND Convergence Medical Science Education Research Center, Pusan National University School of Medicine, Yangsan, South Korea, 3Department of Biochemistry, Dong-eui University College of Korean Medicine, Busan, South Korea, 4Department of Oral Biochemistry, Dental and Life Science Institute, School of Dentistry, Pusan National University, Yangsan, South Korea, 5Division of Cardiology, Department of Internal Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea, 6Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea, 7Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea, 8Department of Nephrology and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea, 9Anti-Aging Research Center and Core-Facility Center for Tissue Regeneration, Dong-eui University, Busan, South Korea

In retinal pigment epithelial (RPE) cells, transforming growth factor-beta (TGF-β) plays a critical role in epithelial-mesenchymal transition (EMT), which contributes to various fibrotic retinal disorders. In the present study, we investigated the effect of recombinant human cluster of differentiation 82 (rhCD82), a tumor metastasis suppressor, on TGF-β1-induced EMT in human RPE cell line APRE-19. The results show that TGF-β1 significantly enhanced cell migration, invasion and the expression of EMT-mediated factors in APRE-19 cells. However, rhCD82 markedly inhibited cell mobility and the expression of epithelial marker, zonula occludens-1, as well as increased the expression of mesenchymal markers, such as vimentin and α-smooth muscle actin in TGF-β1-treated APRE-19 cells. In addition, TGF-β1 upregulated the phosphorylation of Smad, extracellular signal regulated kinase (ERK) and glycogen synthase kinase-3β (GSK-3β), but only phosphorylation of Smad was suppressed by rhCD82. Noteworthy, rhCD82 greatly suppressed the expression of TGF-β receptor I (TGFRI), TGFRII and integrins in TGF-β1-treated APRE-19 cells. In particular, the result of molecular docking analysis and structural modeling show that rhCD82 partially interacts with the TGF-β1 receptor.
Introduction

Retinal pigment epithelial (RPE) cells, which are located at the outermost layer of the posterior segment of the eye, maintain the functional integrity of the photoreceptors and chorioid and act as a selective barrier (Zhou et al., 2020). Oxidative stress, inflammation and mechanical injury lead to RPE cell damage, which ultimately results in loss of RPE function (Pastor et al., 2002; Choi et al., 2012). RPE dysfunction is involved in the development of various fibrotic retinal disorders, including proliferative vitreoretinopathy (PVR), diabetic retinopathy (DR), and age-related macular degeneration (AMD) (Choi et al., 2012; Zhou et al., 2020). Numerous studies have established that RPE cells undergo epithelial-mesenchymal transition (EMT) during AMD, which is characterized by the acquisition of a phenotype to mesenchymal cells through the loss of cell junction and apical-basal polarity (Takahashi et al., 2010; Zhou et al., 2020). EMT is triggered by multiple extracellular ligands, such as transforming growth factor-beta (TGF-β), matrix (ECM) remodeling proteins (Saito, 2013). This EMT process is mediated by the regulation of Smad-dependent or Smad-independent signaling (Zhou et al., 2020). In this regard, numerous studies have suggested that blocking TGF-β pathway, which is caused by rhCD82 interaction with TGFβRs and integrins, suggesting new insight into CD82 as a potential therapeutic strategy in fibrotic retinal disorders.

KEYWORDS
epithelial-mesenchymal transition (EMT), fibrotic retinal disorders, recombinant human cluster of differentiation 82 (rhCD82), retinal pigment epithelial (RPE), transforming growth factor-beta (TGF-β)

Materials and methods
Chemicals and reagents

rhCD82 protein (catalog No. 12275-H08H) was purchased from Sino Biological Inc. (Beijing, China). A DNA sequence encoding the second extracellular domain of human CD82 (P27701-1) (Gly 111-Leu 228) was fused with a poly histidine tag at the C-terminus and a signal peptide at the N-terminus.
Human recombinant TGF-β1 was obtained from R&D Systems Inc. (Minneapolis, MN, United States).

Retinal pigment epithelial cell culture

ARPE-19, a human RPE cell line, was obtained from the American Type Culture Collection (Manassas, MD, USA). The cells were grown to 70–80% confluence and maintained in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12; Invitrogen-Gibco, Carlsbad, CA, United States) supplemented with 10% fetal bovine serum at 37°C in a 5% CO₂ incubator. ARPE-19 cells from passages 15-20 were used for all experiments. The concentration of 10 ng/ml were selected for TGF-β1, as previous study (Li et al., 2011).

Cell viability

The viability of cells was measured using a 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1; Roche Diagnostics, Indianapolis, IN, United States) assay, according to the manufacturer’s instructions. Briefly, the cells were seeded at 1×10⁴ cells/well in 96-well plates for 24 h and pretreated with or without the desired concentration of rhCD82 for 1 h. Subsequently, 10 ng/ml TGF-β1 was added for 24 h, and then WST-1 substrate was added to the cells for 2 h. The color development was measured at 450 nm using a microplate spectrophotometer (Genius, Männedorf, Switzerland). The results were expressed as the percentage of the optical density of treated cells relative to that of untreated controls.

Cell migration assay

Scratch wound closure assays and Transwell invasion assays of confluent ARPE-19 cells were carried out as described previously (Justus et al., 2014; Yu et al., 2017). For the scratch wound closure assay, the wound lines were made by scratching with a 200 μl pipette tip and pretreated with or without rhCD82 (100–400 ng/ml) for 1 h, and then 10 ng/ml TGF-β1 was added for 24 h. The width of the wound area was recorded under an inverted microscope (Carl Zeiss, Oberkochen, Germany). For the Transwell invasion assay using a transwell chamber system (Corning, Arizona, United States), 1×10⁵ cells/well were seeded in a Matrigel™ (BD Biosciences, Bedford, MA, United States)-coated insert chamber with 200 μl of serum-free medium. The bottom chamber received 10% FBS-containing DMEM/F-12 medium with or without rhCD82 (100–400 ng/ml) and 10 ng/ml TGF-β1. After 48 h, the cells were fixed in 4% poly-methanol for 15 min at room temperature and the invasive cells were stained with 10% Giemsa solution (Sigma–Aldrich Chemical Co., St. Louis, MO, United States) for 20 min at room temperature. Five fields of view were selected at random and observed under a microscope, and stained cells were quantitatively analyzed using the “threshold tool” of ImageJ® (National Institutes of Health, Bethesda, MD, United States).

Immunoblot analysis

The cells were pretreated with or without rhCD82 for 1 h and additionally incubated with 10 ng/ml TGF-β1 for 24 h. As previously described, cells were harvested, and total protein lysates were extracted (Lee et al., 2020), 40 μg of protein were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5% skim milk in Tris-buffered saline containing 0.1% Tween 20, subsequently probed with primary antibodies overnight at 4°C, and then immunoblotted with the corresponding secondary antibodies for 1 h at room temperature. Information on the antibodies used for immunoblot analysis is summarized in Supplementary Table S1. The membranes were then exposed to enhanced chemiluminescence solution (Thermo Fisher Scientific) and visualized using a LAS-3000 Imaging System (Fujifilm Image Reader, Valhalla, NY, USA).

Immunofluorescence analysis

Immunofluorescence staining was performed as previously described (Park et al., 2019). After the indicated treatment, the cells were fixed with 4% paraformaldehyde, permeabilized in 0.5%/triton X-100 and then blocked with 2% bovine serum albumin (Sigma–Aldrich Chemical Co.). The cells were probed with anti-ZO-1 (catalog No. 13663, Cell Signaling Technology, Beverly, MA, United States), anti-vimentin (catalog No. sc-6260, Santa Cruz Biotechnology, Santa Cruz, CA, United States), anti-α-SMA (catalog No. 53-9760-82, Thermo Fisher Scientific, Waltham, MA, United States), anti-integrin β1 (catalog No. ab30394, Abcam Inc., Cambridge, United Kingdom), anti-integrin αvβ5 (catalog No. ab177004, Abcam Inc.), anti-TGFβ receptor I (TGFRI; catalog No. sc-518086, Santa Cruz Biotechnology), and anti-TGFβ receptor II (TGFRII; catalog No. orb763093, Biorbyt Ltd., Cambridge, UK) antibodies at 4°C overnight. Subsequently, the cells were incubated with Alexa Fluor 488-labeled goat anti-rabbit immunoglobulin G (IgG; catalog No. A11008, Thermo Fisher Scientific), Alexa Fluor 488-labeled goat anti-mouse IgG (catalog No. A11001, Thermo Fisher Scientific), and Alexa Fluor 568-labeled goat anti-mouse IgG (catalog No. A11004, Thermo Fisher Scientific) antibodies for 1 h in the dark. The cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI; Sigma–Aldrich Chemical Co.) at RT for 10 min. After washing cells with PBS,
the cells were mounted and visualized by confocal laser scanning microscopy (Carl Zeiss, Oberkochen, Germany).

Molecular docking and structure modeling

To identify the interacting residues in the protein–protein binding complex between rhCD82 and integrin αv, integrin β1, and TGF-β receptors, the three-dimensional (3D) structures of TGF-β, integrin αv, integrin β1, and integrin β5 were obtained from the Protein Data Base (PDB; https://www.rcsb.org) (Prlic et al., 2016). Because human TGFRI, TGFRII, and hCD82 proteins do not have solved structures in PDB, the 3D structure of these proteins was searched in AlphaFold (https://alphafold.ebi.ac.uk) (Varadi et al., 2022). The complexes of hCD82/TGFRI, hCD82/TGFRII, hCD82/integrin αv, and hCD82/integrin αv were bound, and the most stable complex was selected from the top 10 complexes obtained from the ZDOCK server (https://zdock.umassmed.edu) (Pierce et al., 2014). The hCD82/integrin β5 complex was excluded because the size might be very large, and it was impossible to analyze. The molecular docking complex was analyzed and visualized for the interactions between the proteins using the PyMOL molecular graphics system (Schrodinger, Inc., New York, NY, United States, https://pymol.org).

Statistical analysis

Data are presented as the mean ± standard deviation. Analysis of variance (ANOVA) and Tukey’s post-hoc analyses were performed for comparisons between groups using GraphPad Prism 5.03 (GraphPad Software Inc., La Jolla, CA, United States). Statistical significance was set at p < 0.05.

Results

rhCD82 has No cytotoxicity in AREP-19 cells

To select a reasonable concentration of rhCD82 to be used for the efficacy evaluation of TGF-β1-mediated cellular changes, ARPE-19 cells were exposed to various concentrations of rhCD82 for 24 h. Figure 1 shows that rhCD82 had no cytotoxicity at concentrations up to 800 ng/ml in ARPE-19 cells with or without TGF-β1. Treatment with 10 ng/ml TGF-β1 slightly enhanced cell viability, but the level was not significantly different from that in untreated control cells. In addition, pretreatment with rhCD82 showed a slight decrease in cell viability in TGF-β1-stimulated ARPE-19 cells, whose levels were similar at concentrations above 400 ng/ml rhCD82, whereas these values were also not significantly different from those of control cells.

rhCD82 suppresses the cell migration of transforming growth factor-beta-stimulated AREP-19 cells

To investigate the effect of rhCD82 on migratory activity, a critical phenotype of EMT, in TGF-β1-stimulated ARPE-19 cells, we performed scratch wound closure and Transwell invasion assays. As a result of the scratch wound closure assay, treatment with TGF-β1 markedly enhanced the migration of cells 24 h after wounding to 190.48% of the control (Figures 2A,C). In contrast, pretreatment with rhCD82 significantly suppressed the closure in the presence of TGF-β1 in a dose-dependent manner. Similarly, the results of the Transwell invasion assay also showed that TGF-β1 gradually increased the population of invasive cells to 260.47%, of control cells whereas rhCD82 markedly decreased TGF-β1-induced cell invasion to 170.07% and 113.98% in a dose-dependent manner (Figures 2B,D).

rhCD82 suppresses transforming growth factor-beta1-induced epithelial-mesenchymal transition in ARPE-19 cells

To assess whether the inhibitory effect of rhCD82 on TGF-β1-induced cell migration is associated with the regulation of EMT, we analyzed the expression of EMT markers. Figure 3 shows that the expression of ZO-1, an epithelial marker, was markedly downregulated in TGF-β1-stimulated cells, while it was greatly recovered by pretreatment with rhCD82. Furthermore, the expression of mesenchymal markers, including vimentin and α-SMA, was strongly enhanced following TGF-β1 treatment, whereas this overexpression by TGF-β1 was substantially suppressed by rhCD82.
rhCD82 attenuates transforming growth factor (TGF)-β1-mediated epithelial-mesenchymal transition of ARPE-19 cells through downregulation of the smad-dependent signaling pathway

To further verify the downstream mechanism by which TGF-β1 regulates EMT and migration, we investigated the expression of TGF-β-involved signaling cascades, including Smad dependent, Smad-independent and integrin-dependent pathways. As shown in Figure 4A, TGF-β1 conspicuously increased the phosphorylation of Smad, whereas the upregulation of p-Smad by TGF-β1 was markedly decreased in rhCD82-treated cells. Meanwhile, although the phosphorylation of extracellular signal regulated kinase (ERK) was elevated by TGF-β1, the upregulated expression of p-ERK...
was not changed by rhCD82 (Figure 4B). Furthermore, the expression of total ERK was also not altered in TGF-β1- and rhCD82-exposed cells. In addition, the expression and phosphorylation of c-Jun N-terminal kinase (JNK) and p38 were not altered after treatment with TGF-β1 and rhCD82. Likewise, the phosphorylation of glycogen synthase kinase-3β (GSK-3β) was also upregulated in TGF-β1-treated cells, while the increase in p-GSK-3β was not reversed in rhCD82 (Figure 4C). Moreover, the phosphorylation and expression of focal adhesion kinase (FAK), steroid receptor

FIGURE 3
rhCD82 suppresses TGF-β1-induced epithelial-to-mesenchymal transition in ARPE-19 cells. The cells were pretreated with or without 400 ng/ml rhCD82 for 1 h and additionally incubated with 10 ng/ml TGF-β1 for 24 h. Subsequently, the cells were immunostained with the epithelial marker zonula occludens-1 (ZO-1; green) and the mesenchymal markers vimentin (red) and α-smooth muscle actin (α-SMA; green). 4',6'-Diamidino-2-phenylindole (DAPI; blue) was used to counterstain the nuclei. The stained cells were observed under a confocal laser scanning microscope (scale bar, 50 μm).
coactivator (Src), protein kinase B (Akt) and β-catenin did not change following TGF-β1 and rhCD82.

**rhCD82 inhibits the expression of transforming growth factor-beta1 receptors and integrins in transforming growth factor-beta1-stimulated ARPE-19 cells**

To evaluate the effect of rhCD82 on the expression of integrins and TGF-β receptors following TGF-β1 exposure, we performed immunofluorescence analysis for TGFR1, TGFR2, integrin β1, and integrin αvβ5. Figures 5A,B show that the expression of TGFRs, such as TGFR1 and TGFR2, was strongly increased in TGF-β1-stimulated ARPE-19 cells. In contrast, the overexpression of TGFR1 and TGFR2 by TGF-β1 was notably suppressed by pretreatment with rhCD82. This result was consistent with the finding from immunofluorescence analysis for the expression of integrin β1 and integrin αvβ5, as shown in Figures 5C,D.

**hCD82 directly interacts with the TGFR1, TGFR1, integrin β1, and integrin αv**

To predict whether hCD82 interacts with TGFR and integrins or whether it may prevent the binding of TGF-β1 to TGFRs on the cell surface, we performed molecular docking analysis using the ZDOCK server. As shown in Figures 1, 2, different types of interactions of hCD82 with TGFRs and integrins were visualized by PyMOL. Figures 6A,E, Figures 7A,E represent the surface of the protein–protein interaction. In addition, a ribbon cartoon representation of the interacting complex is presented in Figures 6B,F and Figures 7B,F. As a result of the analysis of the interacting residues of the docking complex and its covalent bound distance, hCD82 bound to TGFR1 in five parts (Figures 6C,D). The first covalent bond between residues Arg 237 of TGFR1 and Gln 225 of CD82 was a distance of 3.5 Å (Table 1). The second covalent bond between residues Glu 238 of TGFR1 and Leu 224 of hCD82 was a distance of 3.0 Å. The third covalent bond between residues Lys 337 of TGFR1 and Gln 146 of CD82 was a distance of 3.1 Å. The last two covalent bonds between residues Val 432 of TGFR1 and Asn...
184 of CD82 were a distance of 2.6 Å and 2.3 Å, respectively. Meanwhile, CD82 interacted with TGFRII in seven regions (Figures 6G,H and Table 1). Among them, the covalent bond between residues Asp 469 of TGFRII and Asn 157 of hCD82 had distances of 2.3 Å and 1.9 Å, respectively. Additionally, two covalent bonds between residues Glu 466 of TGFRII and Asp 160 of hCD82 were observed at distances of 3.4 Å and 2.7 Å, respectively. Furthermore, the residues Try 412 of hCD82 bound with Asp 218 of integrin αv, and the distance of its covalent bond is 3.2 Å (Figures 7C,D and Table 1). Aside from these, hCD82 interact with five integrin αv residues: Val 274, Gly 272, His 292, Thr 289, and Thr 178 (Figures 7G,H and Table 1).
Discussion

Tetraspanins are expressed on the intracellular membrane and cell surface and control various biological events, including antigen presentation, cell signal transduction, adhesion, migration and motility (Yan et al., 2021). CD82, one of the established human tetraspanins, is well known as a tumor metastasis suppressor gene in various types of cancers (Feng et al., 2015; Yan et al., 2021). CD82 consists of two extracellular loops with its N- and C-termini, four transmembrane domains and a small inner cytoplasmic loop (Mazurov et al., 2007; Hochheimer et al., 2019). Importantly, the large extracellular loop (LEL; Gly 111-Leu 228) of hCD82 interacts with specific membrane partners, such as integrins, and is essential for the biological activities of tetraspanins (Wright et al., 2004; Ho et al., 2006; Mazurov et al., 2007). Interestingly, a recent study demonstrated that recombinant protein for LEL of hCD82 directly bound to vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), resulting in antiangiogenic and antimetastatic effects (Lee et al., 2021). Additionally, noteworthy, most retinal disorders, including AMD, DR, and retinopathy of prematurity, are involved in inflammation, angiogenesis, and EMT-driven fibrosis, which is accompanied by increased motility (Dreyfuss et al., 2015).
Accumulated evidence has shown that CD82 is a potent tumor suppressor (Yan et al., 2021). Numerous studies have reported that CD82 is downregulated in malignant tumors of various organs, including the lung, breast, ovary, and liver (Feng et al., 2015; Yan et al., 2021). Currently, Lee et al demonstrated that administration of the mimic full-length LEL of CD82 and the selective 10-mer peptide of CD82 LEL markedly suppressed tumor angiogenesis and growth in melanoma, prostate cancer and pancreatic carcinoma (Lee et al., 2021). Furthermore, another recent study suggested that a peptide mimicking the extracellular loop of CD82 inhibited metastasis, invasion, and adherence in in vitro and in vivo pulmonary carcinoma models (Valcourt et al., 2005). Based on these previous studies showing that the anticancer effect of LEL of CD82 is involved in a potential ability to suppress motility and angiogenesis, we hypothesized that its capacity may contribute to protecting against fibrotic retinal disease. Here, we evaluated the effect of rhCD82 protein, a protein mimicking the LEL domain of hCD82 on TGF-β-induced EMT and identified the underlying mechanism in the human RPE cell line ARPE-19. Our findings showed that rhCD82 had significant inhibitory effects on cell migration and invasion in TGF-β1-exposed ARPE-19 cells, and the most significant blockage of motility was noted at a rhCD82 concentration of 400 ng/ml, which was similar to the efficacy of the control. Moreover, we found that TGF-β1-stimulated ARPE-19 cells underwent EMT through the
acquisition of mesenchymal markers and the loss of epithelial markers, while this TGF-β1-mediated EMT progression was noticeably reversed by pretreatment with rhCD82. In the Smad-dependent pathway, TGF-β ligand and the TGF-β receptor complex induce phosphorylation of Smad2 and Smad3 and ultimately promote the transcription of several EMT-regulated genes through nuclear translocation of the Smad complex (Valcourt et al., 2005). Smad-mediated TGF-β signaling can activate integrin-linked kinase (ILK), which interacts with the cytoplasmic domains of integrins and cytoskeletal proteins and leads to the phosphorylation of GSK-3β/β-catenin (Han et al., 2015; Luo, 2017). Our results showed that although TGF-β1 upregulated the phosphorylation of Smad, Smad-independent ERK and integrin-dependent GSK-3β, among them, the phosphorylation of Smad was only downregulated by rhCD82. This finding indicated that the Smad signaling pathway was involved in the suppression of TGF-β1-mediated changes in the EMT phenotype by rhCD82 in ARPE-19 cells. Several previous studies also demonstrated that CD82 represses TGF-β1-mediated EMT through regulation of different signaling pathways in various carcinoma types (Zhu et al., 2017; Zeng et al., 2018; Lee et al., 2019). Lee et al. reported that CD82 downregulated the Wnt signaling pathway, resulting in TGF-β1-mediated EMT in human prostate cancer cells (Lee et al., 2019). In 2017, Zhu et al. demonstrated that CD82 inhibits cell migration and invasion via TGF-β1/Smad signaling in renal cell carcinoma.
Zeng et al. also suggested that CD82 inhibits the invasion and metastasis of esophageal squamous carcinoma cells by blocking the TGF-β1/Smad2/3 signaling pathway (Zeng et al., 2018).

As mentioned earlier, TGF-β has been considered a key regulator of EMT in the pathogenesis of RPE, which activates binding to the heteromorphic TGFRI/TGFRII complex (Zhou et al., 2020). Moreover, several αv integrins are over-expressed during EMT process, but it is expressed at low levels in healthy epithelium (Mamuya and Duncan, 2012). There has been reported that integrins αvβ3, αvβ5, and αvβ6 were all shown to activate TGF-β1 by transmitting cell forces to the latent TGF-β1 complex (Sarrazy et al., 2014). Furthermore, TGF-β signal transduction can be stimulated by binding with integrin αvβ6, which is highly expressed on damaged epithelial cells and carcinoma cells in vitro and in vivo (O’Connor and Gomez, 2014; Munger et al., 1999). Based on these findings, to evaluate the potential of CD82 to bind TGFRs and integrins, which are key transmembrane regulators of TGF-β1 in the RPE, we performed molecular docking analysis using the ZDOCK server. Moreover, we estimated whether it prevents the binding of TGF-β1 to TGFR or integrins on the cell surface. In the current study, we confirmed that the TGF-β1-mediated EMT process is accompanied by upregulation of TGFR1, TGFR2, integrin β1 and integrin αvβ5 in ARPE-19 cells, whereas this event is suppressed in the presence of rhCD82. Additionally, we found that the LEL domain of hCD82 bound with residues 237–432 of TGFR1 and residues 339–466 of TGFR2 containing protein kinase domain (Chaikuad and Bullock, 2016). Furthermore, our finding shown that Thy 142 residue of hCD82 directly interact with Asp 218 residue of integrin αv which is the residue bind with Arg 215 of TGF-β1 (Shi et al., 2011; Dong et al., 2017). These results suggest that the LEL domain of CD82 may directly or indirectly inhibit the binding of TGF-β1 or the TGFR1/II and integrins, resulting TGF-β downstream signal pathway.

Overall, our present findings showed that rhCD82, a partial protein of human CD82 LEL, suppressed TGF-β1-induced EMT of RPE, including increasing migration and invasion, acquisition of mesenchymal phenotype, and overexpression of TGFRs and integrins (Figure 8). This inhibitory effect of rhCD82 on TGF-β1-mediated EMT is associated with the LEL domain of CD82 interacting with TGFR and integrins, and it may prevent the binding of TGF-β1 to TGFR or integrins on the cell surface, which leads to blockade of TGF-β signal transduction via the Smad-dependent pathway. However, the

**FIGURE 8**
Graphical abstract of rhCD82 suppressing TGF-β1-mediated epithelial-mesenchymal transition by blocking the Smad-dependent signal in ARPE-19 cells, which is due to interaction with integrin and TGF-β receptor.
limitations of the present study are the lack of the result for direct interaction with rhCD82 and TGFR and integrins using immunoprecipitation and blitz techniques, although we predicted the interaction using molecular docking and structure modeling. In addition, we considered that the further studies are warranted to identify the effect of rhCD82 on retinal disorders in vivo system. Although further studies still remain to be addressed, our findings suggest the important evidence that the effect of rhCD82 against to the TGF-β1-mediated EMT, and new insight into rhCD82 as a potential therapeutic strategy in fibrotic retinal disorders.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author contributions

HL, J-HH, YC, and JH: conceptualization, methodology, and supervision. HL, J-HH, YK, HH, and AY: investigation and data curation. HH, H-SK, DL, SL, BC, and YC: formal analysis and visualization. HL, J-HH, SL, BC, J-JK, SK, YC, and JH: manuscript writing-original draft preparation, review and editing. HL, J-HH and JH: project administration and funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (Grant No. NRF-2020R1I1A3069714, NRF-2020R1I1A101072777 and NRF-2022R1I1A101070768). In addition, this research was supported by the Korean Fund for Regenerative Medicine (KFRM) grant funded by the Korean government (the Ministry of Science and ICT, the Ministry of Health and Welfare; Grant No. KFRM 21A0502L1-12).

Acknowledgments

Figure 8 was created in part withBioRender.com.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.991056/full#supplementary-material

References

Chaikaad, A., and Bullock, A. N. (2016). Structural basis of intracellular TGF-β signaling: Receptors and smads. Cold Spring Harb. Perspect. Biol. 8 (11), a022111. doi:10.1101/cshperspect.a022111

Chien, H. W., Wang, K., Chang, Y. Y., Hsieh, Y. H., Yu, N. Y., Yang, S. F., et al. (2019). Kaempferol suppresses cell migration through the activation of the ERK signaling pathways in ARPE-19 cells. Environ. Toxicol. 34 (3), 312–318. doi:10.1002/tox.22866

Choi, K., Lee, K., Ryu, S. W., Im, M., Kook, K. H., and Choi, C. (2012). Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Mol. Vis. 18, 1010–1020.

Dong, X., Zhan, B., Iacob, R. E., Zhu, J., Koksal, A. C., Lu, C., et al. (2017). Force interacts with macromolecular structure in activation of TGF-β. Nature 542 (7639), 55–59. doi:10.1038/nature21035

Dreyfuss, J. L., Giordano, R. J., and Regatieri, C. V. (2015). Ocular angiogenesis. J. Ophthalmol. 2015, 892043. doi:10.1155/2015/892043

Dvashi, Z., Goldberg, M., Adir, O., Shapira, M., and Pollack, A. (2015). TGF-β1 induced transdifferentiation of rpe cells is mediated by TAK1. PLoS One 10 (4), e0122229. doi:10.1371/journal.pone.0122229

Feng, J., Huang, C., Wren, J. D., Wang, D. W., Yan, J., Zhang, J., et al. (2015). Tetraspanin CD82: A suppressor of solid tumors and a modulator of membrane heterogeneity. Cancer Metastasis Rev. 34 (4), 619–633. doi:10.1007/s10555-015-9585-x

Gabbiani, G. (2003). The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200 (4), 500–503. doi:10.1002/path.1427

Han, J. W., Lyu, J., Park, Y. J., Jang, S. Y., and Park, T. K. (2015). Wnt/β-Catenin signaling mediates regeneration of retinal pigment epithelium after laser photocoagulation in mouse eye. Invest. Ophthalmol. Vis. Sci. 56 (13), 8314–8324. doi:10.1167/iovs.15-18359

Hinton, D. R., He, S., Jin, M. L., Barron, E., and Ryan, S. J. (2002). Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond) 16 (4), 422–428. doi:10.1038/sj.eye.6700190
